^
    TNFRSF8 positive
    HL
    brentuximab vedotin
    Sensitive
    :
    A1
    No biomarker
    HL
    pembrolizumab
    Sensitive
    :
    A1
    No biomarker
    HL
    carmustine
    Sensitive
    :
    A1
    No biomarker
    HL
    nivolumab
    Sensitive
    :
    A1
    No biomarker
    HL
    R-CHOP
    Sensitive
    :
    A2
    No biomarker
    HL
    rituximab
    Sensitive
    :
    A2
    No biomarker
    HL
    R-CVP
    Sensitive
    :
    A2
    No biomarker
    HL
    brentuximab vedotin
    Sensitive
    :
    A2
    No biomarker
    HL
    bortezomib
    Sensitive
    :
    A2
    No biomarker
    HL
    everolimus
    Sensitive
    :
    A2
    No biomarker
    HL
    carboplatin + etoposide oral + bendamustine
    Sensitive
    :
    A2
    No biomarker
    HL
    bendamustine
    Sensitive
    :
    A2
    No biomarker
    HL
    nivolumab + brentuximab vedotin
    Sensitive
    :
    A2
    No biomarker
    HL
    lenalidomide
    Sensitive
    :
    A2
    No biomarker
    HL
    rituximab + bendamustine
    Sensitive
    :
    A2
    No biomarker
    HL
    GemOx
    Sensitive
    :
    A2
    No biomarker
    HL
    ICE
    Sensitive
    :
    A2
    No biomarker
    HL
    ESHAP
    Sensitive
    :
    A2
    No biomarker
    HL
    DHAP
    Sensitive
    :
    A2
    No biomarker
    HL
    R-ESHAP
    Sensitive
    :
    A2
    No biomarker
    HL
    MINE
    Sensitive
    :
    A2
    CHD8 mutation
    HL
    sintilimab
    Resistant
    :
    C3
    CELF2 mutation
    HL
    sintilimab
    Resistant
    :
    C3
    ABCC2 underexpression
    HL
    nivolumab + brentuximab vedotin
    Sensitive
    :
    C3
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES